Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Federal Trade Commission
Harvard Business School
US Army
Merck
Queensland Health
Healthtrust
QuintilesIMS
UBS

Generated: February 25, 2018

DrugPatentWatch Database Preview

CAYSTON Drug Profile

« Back to Dashboard

Which patents cover Cayston, and when can generic versions of Cayston launch?

Cayston is a drug marketed by Gilead and is included in one NDA. There are four patents protecting this drug.

This drug has forty-seven patent family members in eighteen countries.

The generic ingredient in CAYSTON is aztreonam. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aztreonam profile page.
Summary for CAYSTON
Drug patent expirations by year for CAYSTON
Medical Subject Heading (MeSH) Categories for CAYSTON

US Patents and Regulatory Information for CAYSTON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for CAYSTON

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,660,249 Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections ➤ Sign Up
9,345,663 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Sign Up
9,533,000 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections ➤ Sign Up
7,138,419 Process for manufacturing bulk solutions and a lyophilized pure .alpha.-aztreonam lysinate ➤ Sign Up
8,841,286 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for CAYSTON

Supplementary Protection Certificates for CAYSTON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB11/049 United Kingdom ➤ Sign Up PRODUCT NAME: AZTREONAM LYSINE; REGISTERED: UK EU/1/09/543/001 20090921
90027-1 Sweden ➤ Sign Up PRODUCT NAME: AZTREONAMLYSIN; REG. NO/DATE: EU/1/09/543/01 20090921
2011 00021 Denmark ➤ Sign Up
5 Finland ➤ Sign Up
11/024 Ireland ➤ Sign Up PRODUCT NAME: AZTREONAM LYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090923
851 Luxembourg ➤ Sign Up 91851, EXPIRES: 20240921
1353647/01 Switzerland ➤ Sign Up PRODUCT NAME: AZTREONAMLYSIN; REGISTRATION NO/DATE: SWISSMEDIC 59389 06.12.2010
0492 Netherlands ➤ Sign Up PRODUCT NAME: AZTREONAMLYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090923
C0030 France ➤ Sign Up PRODUCT NAME: AZTREONAM LYSINE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/543/001 DU 20090921; REGISTRATION NO/DATE AT EEC: EU/1/09/543/001 DU 20090921
00492 Netherlands ➤ Sign Up PRODUCT NAME: AZTREONAM, NIET IN EEN SAMENSTELLING MET ARGININE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN AZTREONAM, ANDERS DAN EEN ARGININEZOUT, IN HET BIJZONDER ALS AZTREONAMLYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090921
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Cipla
Fish and Richardson
Medtronic
Baxter
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot